Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
BMJ ; 365: l2006, 2019 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-31088853

RESUMO

CLINICAL QUESTION: What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice. CURRENT PRACTICE: Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels >10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. RECOMMENDATION: The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old). HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. THE EVIDENCE: The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years' follow-up. UNDERSTANDING THE RECOMMENDATION: The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.


Assuntos
Hipotireoidismo/tratamento farmacológico , Hormônios Tireóideos/uso terapêutico , Adulto , Idoso , Índice de Massa Corporal , Tomada de Decisões , Técnicas de Apoio para a Decisão , Depressão/tratamento farmacológico , Depressão/etiologia , Fadiga/tratamento farmacológico , Fadiga/etiologia , Feminino , Humanos , Hipotireoidismo/sangue , Hipotireoidismo/complicações , Hipotireoidismo/diagnóstico , Qualidade de Vida , Hormônios Tireóideos/efeitos adversos , Tireotropina/sangue , Tiroxina/sangue , Incerteza
2.
BMJ ; 365: [1-9], May 14, 2019.
Artigo em Inglês | BIGG - guias GRADE | ID: biblio-1094958

RESUMO

What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice. Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels >10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying tobecome pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or youngadults (such as those ≤30 years old).


Assuntos
Humanos , Adulto , Hormônios Tireóideos/efeitos adversos , Hormônios Tireóideos/uso terapêutico , Hipotireoidismo/complicações , Hipotireoidismo/diagnóstico , Hipotireoidismo/prevenção & controle , Adulto
4.
BMJ ; 3632018.
Artigo em Inglês | BIGG - guias GRADE | ID: biblio-1015429

RESUMO

What is the best way to use oxygen therapy for patients with an acute medical illness? A systematic review published in the Lancet in April 2018 found that supplemental oxygen in inpatients with normal oxygen saturation increases mortality.1 Its authors concluded that oxygen should be administered conservatively, but they did not make specific recommendations on how to do it. An international expert panel used that review to inform this guideline. It aims to promptly and transparently translate potentially practice-changing evidence to usable recommendations for clinicians and patients.2 The panel used the GRADE framework and following standards for trustworthy guidelines.3


Assuntos
Humanos , Oxigênio/sangue , Oxigenoterapia/métodos , Oximetria/classificação , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/terapia , Oxigenoterapia , Doença Aguda/terapia , Infarto do Miocárdio
5.
Int J Public Health ; 61(2): 257-67, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26825455

RESUMO

OBJECTIVES: E-cigarettes are increasingly popular as smoking cessation aids. This review assessed the efficacy of e-cigarettes for smoking cessation as well as desire to smoke, withdrawal symptoms, and adverse events in adult smokers. METHODS: A systematic review was conducted. Studies comparing e-cigarettes to other nicotine replacement therapies or placebo were included. Data were pooled using meta-analysis. RESULTS: Of 569 articles, 5 were eligible. Study participants were more likely to stop smoking when using nicotine e-cigarettes (43/489, 9 %) versus placebo e-cigarettes (8/173, 5 %); however, this difference was not statistically significant (RR 2.02; 95 % CI 0.97, 4.22). The pooled effect estimates for the desire to smoke (RR -0.22; 95 % CI -0.80, 0.36), irritability (RR -0.03; 95% CI -0.38, 0.31), restlessness (RR -0.03; 95 % CI -0.42, 0.35), poor concentration (RR -0.01; 95 % CI -0.35, 0.32), depression (RR -0.01; 95 % CI -0.22, 0.20), hunger (RR -0.01; 95 % CI -0.32, 0.30), and average number of non-serious adverse events (RR -0.09; 95 % CI -0.28, 0.46) were not statistically significantly different. Only one study reported serious adverse events with no apparent association with e-cigarette use. CONCLUSIONS: Limited low-quality evidence of a non-statistically significant trend toward smoking cessation in adults using nicotine e-cigarettes exists compared with other therapies or placebo. Larger, high-quality studies are needed to inform policy decisions.


Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Nicotina , Abandono do Hábito de Fumar/métodos , Humanos , Nicotina/administração & dosagem , Nicotina/efeitos adversos , Fumar/efeitos adversos , Síndrome de Abstinência a Substâncias , Dispositivos para o Abandono do Uso de Tabaco
6.
J Hosp Infect ; 92(2): 130-9, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26601607

RESUMO

BACKGROUND: Postoperative infections, particularly surgical site infections (SSIs), cause significant morbidity and mortality. Probiotics or synbiotics are a potential prevention strategy. AIM: To evaluate the efficacy of probiotics/synbiotics for reducing postoperative infection risk following abdominal surgery. METHODS: We searched AMED, Central, CINAHL, Embase, Medline, and grey literature for randomized controlled trials of elective abdominal surgery patients administered probiotics or synbiotics compared to placebo or standard care. Primary outcome was SSIs. Secondary outcomes were adverse events, respiratory tract infections (RTIs), urinary tract infections (UTIs), combined infections, length of hospital stay, and mortality. Using random-effects meta-analyses, we estimated the relative risk (RR) or mean difference (MD) and 95% confidence interval (CI). Tests were performed for heterogeneity, subgroup and sensitivity analyses were conducted, and the overall evidence quality was graded. FINDINGS: We identified 20 trials (N = 1374 participants) reporting postoperative infections. Probiotics/synbiotics reduced SSIs (RR: 0.63; 95% CI: 0.41-0.98; N = 15 studies), UTIs (RR: 0.29; 95% CI: 0.15-0.57; N = 11), and combined infections (RR: 0.49; 95% CI: 0.35-0.70; N = 18). There was no difference between groups for adverse events (RR: 0.89; 95% CI: 0.61-1.30; N = 6), RTIs (RR: 0.60; 95% CI: 0.36-1.00; N = 14), length of stay (MD: -1.19; 95% CI: -2.94 to 0.56; N = 12), or mortality (RR: 1.20; 95% CI: 0.58-2.48; N = 15). CONCLUSION: Our review suggests that probiotics/synbiotics reduce SSIs and UTIs from abdominal surgeries compared to placebo or standard of care, without evidence of safety risk. Overall study quality was low, owing mostly to imprecision (few patients and events, or wide CIs); thus larger multi-centered trials are needed to further assess the certainty in this estimate.


Assuntos
Infecções Intra-Abdominais/prevenção & controle , Probióticos/administração & dosagem , Infecção da Ferida Cirúrgica/prevenção & controle , Simbióticos/administração & dosagem , Humanos , Placebos/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
7.
Lik Sprava ; (1): 88-90, 1999.
Artigo em Ucraniano | MEDLINE | ID: mdl-10424010

RESUMO

Over the period of 1992-1996, the number of patients discharging atypical mycobacteria was found out to have gotten increased. The clinical picture of the pathological processes induced by the above-named mycobacteria is similar to that seen in tuberculosis. An untimely diagnosis of mycobacterioses together with difficulties in their recognition suggest a great need for quest for novel clinical and laboratory methods of detection and diagnosis as well as efficient treatment option for these diseases.


Assuntos
Infecções por Mycobacterium não Tuberculosas/diagnóstico , Adulto , Idoso , Antibacterianos/uso terapêutico , Quimioterapia Combinada , Humanos , Pulmão/diagnóstico por imagem , Pulmão/microbiologia , Pessoa de Meia-Idade , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Infecções por Mycobacterium não Tuberculosas/microbiologia , Micobactérias não Tuberculosas/isolamento & purificação , Radiografia , Fatores de Tempo , Tuberculose Pulmonar/diagnóstico , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA